https://www.selleckchem.com/products/PIK-90.html
We assessed the effect of mebeverine in the enhancement of the orthotopic bladder substitute continence. A randomized trial was carried out for incontinent adult male patients during the first year post-orthotopic bladder substitute surgery. Patients were allocated to receive mebeverine 135 mg or placebo 3 times a day for only 3 months. The primary outcome was to compare the continence improvement between groups, assessed by the urinary domain of the Bladder Cancer Index and sanitary pad use. The secondary outcomes were to assess the saf
Like
Comment
Share
